Volltext-Downloads (blau) und Frontdoor-Views (grau)

The upside of being a digital pharma player

  • We investigated the state of artificial intelligence (AI) in pharmaceutical research and development (R&D) and outline here a risk and reward perspective regarding digital R&D. Given the novelty of the research area, a combined qualitative and quantitative research method was chosen, including the analysis of annual company reports, investor relations information, patent applications, and scientific publications of 21 pharmaceutical companies for the years 2014 to 2019. As a result, we can confirm that the industry is in an ‘early mature’ phase of using AI in R&D. Furthermore, we can demonstrate that, despite the efforts that need to be managed, recent developments in the industry indicate that it is worthwhile to invest to become a ‘digital pharma player’.

Export metadata

Additional Services

Search Google Scholar

Statistics

frontdoor_oas
Metadaten
Author of HS ReutlingenSchuhmacher, Alexander
DOI:https://doi.org/10.1016/j.drudis.2020.06.002
ISSN:1359-6446
eISSN:1878-5832
Erschienen in:Drug discovery today
Publisher:Elsevier
Place of publication:Amsterdam
Document Type:Journal article
Language:English
Publication year:2020
Volume:25
Issue:9
Page Number:6
First Page:1569
Last Page:1574
DDC classes:610 Medizin, Gesundheit
Open access?:Nein
Licence (German):License Logo  In Copyright - Urheberrechtlich geschützt